Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)
Richard T. Penson, Ricardo Villalobos-Valencia, Nicoletta Colombo, Charles A. Leath, Mariusz Bidziński, Jae‐Weon Kim, Joo‐Hyun Nam, Radosław Mądry, Carlos Hernández, Paulo Mora, Sang‐Young Ryu, Tsveta Milenkova, Elizabeth Lowe, Natalia Lukashchuk, John McNamara, Giovanni Scambia
Topics & Concepts
MedicineOlaparibInternal medicineOncologyClinical endpointTopotecanGemcitabineChemotherapyOvarian cancerProgression-free survivalCarboplatinUrologyRandomized controlled trialCancerCisplatinChemistryBiochemistryGenePoly ADP ribose polymerasePolymerasePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer